Lysosome-based antiviral preparation as well as preparation method and application thereof

By fixing virus-binding molecules on the surface of lysosomes, capturing and internalizing the virus, and using hydrolytic enzymes in the lysosome to degrade the virus, the problem of existing antiviral vaccines being invalid due to virus mutation is solved, and efficient clearance and reduction of the virus is achieved The risk of escape infection is suitable for people with low immunity and severe patients.

CN118903457AActive Publication Date: 2024-11-08INSTITUTE OF PROCESS ENGINEERING CHINESE ACADEMY OF SCIENCES
View PDF 7 Cites 0 Cited by

Patent Information

Application Number
CN202310506395.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-05-08
Publication Date
2024-11-08
Estimated Expiration
2043-05-08

AI Technical Summary

Technical Problem

The existing antiviral vaccines are ineffective due to viral mutation and are not applicable to people with low immunity and severe patients. An efficient antiviral treatment strategy that is not disturbed by viral mutation is urgently needed.

Method used

Develop a lysosome-based antiviral preparation that captures and internalizes the virus by immobilizing virus-binding molecules such as ACE2 receptors on the surface of the lysosome, and uses hydrolase in the lysosome to degrade the virus, ensuring the virus’s variants Efficiently cleared.

Benefits of technology

This preparation can effectively eliminate viruses, reduce the risk of escape infection, and is not affected by viral mutations. It is suitable for people with low immunity and severe patients, significantly inhibiting viral infection.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118903457A_ABST
    Figure CN118903457A_ABST
Patent Text Reader

Abstract

The invention discloses a lysosome-based antiviral preparation as well as a preparation method and application thereof. According to the lysosome preparation disclosed by the invention, firstly, a virus is captured by utilizing the affinity of a virus binding molecule modified on the surface of the lysosome and a ligand protein mediated by the surface of the virus, then the virus is internalized to be completely isolated from a host cell, and finally, the virus is degraded by utilizing hydrolase in the lysosome, so that the possibility of escape or continuous infection is reduced. Besides, the lysosome preparation disclosed by the invention does not lose curative effect due to virus mutation, any virus variant combined with the virus binding molecule is sensitive to lysosome trap-mediated clearance, the defects of current virus treatment can be made up, and the virus can be efficiently removed.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of pharmaceutical preparations, and in particular to a lysosome-based antiviral preparation, a preparation method of the antiviral preparation and its application in antiviral treatment, especially in anti-coronavirus and influenza virus treatment. Background Art

[0002] Viruses are one of the main pathogens that threaten human health. Vaccination is the most important measure to prevent and control viral infections such as coronavirus infections. However, due to the rapid mutation of viruses such as coronaviruses, antigenic drift may occur, posing a risk of vaccine failure. In addition, vaccination is not suitable for people with low immunity such as the elderly and children, and for critically ill patients who have been infected with the virus, and more efficient antiviral treatment strategies are urgently needed.

[0003] At present, it is necessary to develop preparations that are not affected by viral mutations and can specifically and directly eliminate viruses, thereby inhibiting viral infection in the body, alleviating the symptoms caused by the virus, and improving the quality of life of patients.

[0004] The information in the background technology is only for illustrating the general background of the present invention and should not be regarded as admitting or suggesting in any form that such information constitutes the prior art known to a person skilled in the art. Summary of the invention

[0005] In order to solve at least some of the technical problems in the prior art, the present invention provides a lysosome-based antiviral preparation. Specifically, the present invention includes the following contents.

[0006] In a first aspect, the present invention provides a lysosome-based antiviral preparation, which includes a lysosome and a virus-binding molecule located on the surface of the lysosome or a precursor for producing the virus-binding molecule.

[0007] In certain embodiments, according to the lysosome-based antiviral preparation of the present invention, the lysosome is derived from any cell that can produce lysosomes. In certain embodiments, according to the lysosome-based antiviral preparation of the present invention, the cell is a macrophage, which includes at least one of a primary macrophage, an M1 macrophage, and an engineered macrophage.

[0008] In certain embodiments, according to the lysosomal-based antiviral formulation of the present invention, the virus-binding molecule comprises a receptor for a viral surface protein.

[0009] In certain embodiments, according to the lysosome-based antiviral formulation of the present invention, the receptor is bound to the lysosome via a linker molecule.

[0010] In certain embodiments, according to the lysosome-based antiviral preparation of the present invention, the linker molecule comprises a hydrophobic end, a spacer arm and a binding domain, and the binding domain is capable of binding to the receptor.

[0011] In certain embodiments, according to the lysosomal-based antiviral formulation of the present invention, the receptor is a modified receptor.

[0012] In certain embodiments, according to the lysosomal-based antiviral formulation of the present invention, the precursor comprises sialyl cytidine monophosphate and optionally a sialyltransferase.

[0013] The second aspect of the present invention provides a method for preparing the lysosome-based antiviral preparation described in the first aspect.

[0014] The third aspect of the present invention provides the use of lysosomes in the preparation of drugs for preventing and controlling viral infections, wherein the lysosomes are modified to have virus-binding molecules on their surfaces.

[0015] The fourth aspect of the present invention provides the use of a combination of a lysosome and a precursor for producing a virus-binding molecule on the surface of a lysosome in the preparation of a drug for preventing and controlling viral infection.

[0016] In certain embodiments, according to the use of the present invention, wherein the prevention and control comprises: Reducing, reducing the amount of virus in a subject, or eliminating the virus in a subject; or Reduce or attenuate viral activity in a subject.

[0017] The present invention uses the affinity of virus binding molecules and viral ligand proteins such as S / ACE2 to capture viruses, then internalize the viruses to completely isolate them from host cells, and finally use lysosomal hydrolases to degrade the viruses, reducing the possibility of escape or persistent infection. In addition, the lysosomal preparation of the present invention will not lose its efficacy due to viral mutations, and any viral variants bound to the virus binding molecules are sensitive to lysosomal "trap"-mediated clearance. In certain embodiments, the present invention makes up for the deficiencies of current clinical anti-coronavirus treatments and efficiently removes viruses. BRIEF DESCRIPTION OF THE DRAWINGS

[0018] Figure 1 Fluorescence confocal images of LAMP-2 and ACE2 in lysosomal preparations prepared by chemical modification.

[0019] Figure 2 Fluorescence confocal images of LAMP-2 and ACE2, lysosomal preparations prepared by genetic engineering.

[0020] Figure 3 TEM images of lysosomes and lysosomal preparations.

[0021] Figure 4 Lysosome and lysosomal preparation size and potential (size on top, zeta potential on bottom).

[0022] Figure 5 Changes in the enzymatic activities of ACE2 (left), proteases, and nucleases in lysosomal preparations before and after ACE2 protein modification.

[0023] Figure 6 Investigation of the binding ability of lysosomal preparations to pseudoviruses.

[0024] Figure 7 TEM images of pseudovirus internalized in lysosomal preparations and corresponding electron microscopic sections.

[0025] Figure 8 Pseudoviral protein levels.

[0026] Fig. 9 Pseudoviral nucleic acid levels.

[0027] Fig.10 Confocal microscopy images of virus-infected cells.

[0028] Fig.11 Flow cytometry results of virus-infected cells.

[0029] Fig.12 Small animal imaging results after administration of lysosomal preparations.

[0030] Fig.13 The main organ distribution results of the lysosomal preparation 9 hours after administration.

[0031] Fig.14 Routine blood analysis after administration of lysosome preparations (PBS, Lysosome, ACE2, LysoTRAP from left to right in the bar graphs of each group).

[0032] Fig.15 Macrobiochemical analysis after administration of lysosome preparations (from left to right in the bar graphs of each group are PBS, Lysosome, ACE2, and LysoTRAP).

[0033] Fig.16 HE sections of major tissues and organs after administration of lysosomal preparations.

[0034] Figure 17-18 It was shown that the lysosome preparation group significantly inhibited viral infection at the animal level.

[0035] Fig.19The viral copy numbers of the lysosomal preparation groups are shown (PBS, EIDD-2801, RBDantibody, h-lysoTRAP from left to right).

[0036] Fig. 20 The lysosomal preparation group significantly inhibited the expression of viral S protein.

[0037] Fig.21 Nucleic acid load analysis of viral infection (from left to right: PBS, EIDD-2801, RBD antibody, h-lysoTRAP).

[0038] Fig. 22 Immunofluorescence analysis of virus-infected sections.

[0039] Fig.23 Cluster analysis of the therapeutic effects of each medication group.

[0040] Fig.24 Confocal microscopy images of LAMP-2 and SA in lysosomes and anti-influenza virus lysosome preparations prepared by chemical modification.

[0041] Fig.25 Fluorescence confocal images of lysosomes and anti-influenza virus lysosomal preparations LAMP-2 and SA prepared by genetic engineering.

[0042] Fig.26 Body weight changes of mice after viral infection (from top to bottom: NC, LysoTRAP (SA), PBS).

[0043] Fig. 27 Changes in lung weight and lung index of mice after virus infection.

[0044] Fig.28 Analysis of viral nucleic acid load in mice after virus infection. DETAILED DESCRIPTION

[0045] Various exemplary embodiments of the present invention will now be described in detail. This detailed description should not be considered as limiting the present invention, but should be understood as a more detailed description of certain aspects, features, and embodiments of the present invention.

[0046] It should be understood that the terms described in the present invention are only for describing special embodiments and are not intended to limit the present invention. In addition, for the numerical range in the present invention, it should be understood that the upper and lower limits of the scope and each intermediate value therebetween are specifically disclosed. Each smaller range between the intermediate value in any stated value or stated range and any other stated value or intermediate value in the described range is also included in the present invention. The upper and lower limits of these smaller ranges can be independently included or excluded in the scope.

[0047] Unless otherwise indicated, all technical and scientific terms used herein have the same meanings as those generally understood by those skilled in the art. Although the present invention describes only preferred methods and materials, any methods and materials similar or equivalent to those described herein may also be used in the implementation or testing of the present invention. All documents mentioned in this specification are incorporated by reference to disclose and describe the methods and / or materials associated with the documents. In the event of a conflict with any incorporated document, the content of this specification shall prevail.

[0048] Lysosome-based antiviral agents In a first aspect of the present invention, a lysosome-based antiviral preparation is provided, which is an antiviral preparation developed or prepared based on lysosomes, sometimes referred to herein as a "lysosome preparation". In addition, the lysosome preparation of the present invention can capture or further kill viruses, and therefore, the lysosome-based antiviral preparation or lysosome preparation can also be referred to as a lysosome "trap". The three can be used interchangeably herein.

[0049] The lysosome preparation of the present invention comprises lysosome and virus-binding molecules located on the surface of lysosome or precursors for producing the virus-binding molecules.

[0050] Virus binding molecules In the present invention, the virus binding molecule is generally located or fixed on the surface of the lysosome by artificial means, or the virus binding molecule is bound to the surface of the lysosome by modification, or the amount of the virus binding molecule is increased to reach a level sufficient to effectively adsorb or capture the virus. The virus binding molecule is not particularly limited, and can be a universal binding molecule for a variety of different viruses, or a specific binding molecule for a specific virus.

[0051] In the present invention, since the virus-binding molecules are not particularly limited and can be any known type, the lysosomal preparation of the present invention can be prepared as preparations for various different viruses as needed. Therefore, the lysosomal preparation can be understood as a lysosomal preparation platform, and should not be understood as a specific preparation for a specific virus.

[0052] In certain embodiments, the virus binding molecule of the present invention is a virus protein receptor, such as a binding receptor for a protein on the surface of the virus, examples of which include but are not limited to angiotensin converting enzyme 2 (ACE2), sialic acid, cholesterol transport protein NPC1, CD4 protein, etc. Preferably, the virus receptor is a receptor modified so as to be able to bind or be fixed to the surface of the lysosome. Exemplarily, the receptor is covalently bound to the linker molecule after modification. The linker molecule is designed to be able to be inserted into the interior of the lysosomal membrane so as to bind or be fixed to the membrane. In certain embodiments, the linker molecule is designed to include a hydrophobic end, a spacer arm, and a binding domain, and the hydrophobic end is located at the end of the linker molecule for inserting into the interior of the lysosomal membrane to fix the linker molecule. The spacer arm is generally located in the middle of the linker molecule, and is not particularly limited as long as it has a spacing function, and may be, for example, a hydrophilic molecular chain. The binding domain is located at the other end of the linker molecule for binding to the virus receptor molecule.

[0053] In the present invention, the lysosomal preparation can also be designed as a composition consisting of multiple components, wherein at least part of the components are precursors for producing virus binding molecules. Examples of such precursors include reagents or molecules for producing sialic acid on the lysosomal surface, examples of which include sialylcytidine monophosphate and sialyltransferase. In the case of simultaneously comprising both sialylcytidine monophosphate and sialyltransferase, the amounts of the two are not particularly limited, such as sialylcytidine monophosphate and sialyltransferase based on a weight ratio of 1-20:1-5. Generally, it is preferred that the amount of sialylcytidine monophosphate is greater than that of sialyltransferase. For example, 1.5-20:1, 2-20:1, 5-20:1, etc.

[0054] In certain embodiments, the lysosomal preparation of the present invention comprises lysosomes, sialylcytidine monophosphate and sialyltransferase. The mass ratio of lysosomes, sialylcytidine monophosphate and sialyltransferase is generally 50-1000:1-20:1-5. For example, 50-800:1-20:1-5, for example, 50-500:1-20:1-5, or 100-800:6-15:1-5.

[0055] lysosome In the present invention, lysosome is a cell organelle derived from the separation in the cell, and as long as it has the function of decomposing or inactivating the virus, the structure or composition of the lysosome is not particularly limited. Generally speaking, the lysosome contains hydrolases, preferably a combination of multiple hydrolases, particularly acid hydrolases, examples of which include but are not limited to proteases, nucleases, phosphatases, glycosidases, lipases, phosphatases and sulfatase, etc. The inventors found that although the lysosomes of the present invention can decompose or inactivate viruses, they do not hydrolyze virus-binding molecules such as AEC2.

[0056] In the present invention, lysosomes can be obtained by separation from cells or by artificial synthesis. As long as they have the function of decomposing viruses or inactivating them, the method for obtaining lysosomes is not limited. Therefore, lysosomes can be lysosomes existing in natural form, or they can be modified or transformed lysosomes, or they can be artificial lysosomes synthesized completely.

[0057] In certain embodiments, the lysosomes of the present invention are directly separated from cells. The cell source of the lysosome is not particularly limited, and can be any cell source. It is generally a eukaryotic cell, preferably an immune cell, such as a macrophage, examples of which include but are not limited to primary macrophages, M1 macrophages, and engineered macrophages. The present invention can use any of the above cells, or a combination of two or more. In certain embodiments, the cells of the present invention use engineered macrophages, which are genetically engineered to overexpress viral receptor molecules in macrophages.

[0058] In certain embodiments, lysosome of the present invention is obtained by artificial synthesis. For example, the lysosome-like obtained by making the composite hydrolase be contained in the microsphere prepared by artificial membrane material. The components of artificial membrane material include but are not limited to phospholipids, neutral lipids and amphoteric lipids, etc. As phospholipids, examples include but are not limited to natural phospholipids, sphingolipids, glycosphingolipids, phosphatidylcholine, phosphatidylethanolamine, phosphatidic acid, phosphatidylinositol and sphingomyelin, or synthetic phospholipids, such as dipalmitoylphosphatidylcholine, serine or ethanolamine glycerol or the corresponding oleate of these compounds. As neutral lipids, examples include but are not limited to dioleoylphosphatidylethanolamine DOPE, cholesterol, methoxy (polyethylene glycol)-distearyl mPEG-DS. As amphoteric lipids, examples include but are not limited to DPPG, etc.

[0059] Preparation method The second aspect of the present invention provides a method for preparing a lysosomal preparation, sometimes referred to herein as "the preparation method of the present invention", which includes the step of binding virus-binding molecules to the surface of lysosomes, or includes the step of causing isolated lysosomes to produce virus-binding molecules.

[0060] In certain embodiments, the preparation method of the present invention is a chemical modification method, which includes a lysosome separation step and a step of chemically modifying the separated lysosomes. Among them, the lysosome separation step includes a step of cell crushing to obtain a mixed solution, and a step of separating and enriching lysosomes from the mixed solution. Herein, cell crushing can be performed by known methods, including but not limited to homogenization, ultrasound, grinding, etc. The separation or enrichment of lysosomes includes centrifugation, such as differential centrifugation, etc. Next, the separated lysosomes are chemically modified to bind, fix or generate virus binding molecules. Exemplarily, the chemical modification includes adding a connecting molecule to a lysosomal solution for co-incubation, and optionally, further separating the step of free connecting molecules. In another exemplary embodiment, the chemical modification includes adding sialyl cytidine monophosphate and sialyl transferase to a lysosomal solution and co-incubating. The incubation temperature is not limited, generally 20-40°C, such as 30°C, 37°C, etc.

[0061] In certain embodiments, the preparation method of the present invention is a genetic engineering method, which includes a step of overexpressing a virus binding molecule or its precursor in a cell and a step of separating a lysosome. Wherein the step of overexpressing a virus binding molecule or its precursor in a cell includes constructing a vector expressing a virus binding molecule or its precursor gene, and culturing the vector after transferring the vector into the cell to produce a cell containing a virus binding molecule or its precursor in the cell. Preferably, the virus binding molecule or its precursor is fused with a lysosomal localization signal peptide, such as LAMP or its fragment, etc. by genetic engineering means. Herein, examples of vectors are not limited, and generally include target genes, promoters, terminators encoding virus binding molecules or their precursors, or optionally further include marker genes. The vector can use a known vector or a self-constructed vector. Known vectors include plasmid vectors, lentiviral vectors, adenoviral vectors, AAV viral vectors, etc. In this embodiment, the step of separating lysosomes can be the same as the chemical modification method, which will not be repeated here.

[0062] use The third aspect of the present invention provides the use of a combination of a lysosome and a precursor for producing a virus-binding molecule on the surface of a lysosome in the preparation of a drug for preventing and controlling viral infection.

[0063] In the present invention, the form of the drug used to prevent and control viral infection is not limited, and may include any known product. Exemplarily, it includes products for removing viruses from patients, products for preparing virus protection, products for removing influenza viruses from influenza virus patients, products for influenza virus protection, etc.

[0064] In the present invention, prevention and control include reducing or decreasing the amount of virus in the subject, or clearing the virus in the subject, and reducing or weakening the activity of the virus in the subject.

[0065] In the present invention, the drug may further include other ingredients, such as other active ingredients or pharmaceutically acceptable carriers. Pharmaceutically acceptable carriers are well known in the art, and a person of ordinary skill in the art can determine whether they meet clinical standards. Pharmaceutically acceptable carriers include diluents and excipients. Examples of suitable pharmaceutically acceptable carriers include, but are not limited to: (1) Dulbecco's phosphate buffered saline, pH about 7.4, containing or not containing about 1 mg / ml to 25 mg / ml human serum albumin; (2) 0.9% saline (0.9% w / v sodium chloride), 5% (w / v) glucose; (3) may also contain antioxidants such as tryptamine and stabilizers such as Tween 20.

[0066] The medicine of the present invention can be any suitable dosage form. For example, injection, suspension, emulsifier, etc. The pharmaceutical composition of the present invention can be applied to the body by known means. For example, it is delivered to the tissue of interest by intramuscular injection, optionally administered via intravenous, percutaneous, intranasal, oral, mucosal or other delivery methods. Such administration can be carried out via a single dose or multiple doses. It is understood by those skilled in the art that the actual dose to be administered herein can vary depending on a variety of factors to a great extent, such as target cells, biological types or their tissues, the general condition of the subject to be treated, the route of administration, the mode of administration, etc.

[0067] In a preferred embodiment, the drug of the present invention is administered by pulmonary spray injection, which has excellent bioavailability and excellent biosafety. Pulmonary spray injection is particularly suitable for respiratory tract-related viruses. For example, in the lungs, antiviral lysosomal preparations can efficiently clear viruses, first capturing the virus, then internalizing the virus, completely isolating it from the host cell, and finally using lysosomal hydrolases to degrade the virus, reducing the possibility of escape or persistent infection. Embodiment 1

[0068] This example is a preparation example of an exemplary antiviral lysosomal preparation.

[0069] 1. In vitro culture of primary macrophages and extraction of lysosomes Primary macrophages were obtained from the peritoneal cavity of mice. First, a 6% starch broth solution was prepared: 0.03 g of beef extract, 0.1 g of peptone, 0.05 g of sodium chloride, and 0.6 g of soluble starch were weighed and placed in a small beaker, 10 mL of ultrapure water was added, and heated in a microwave oven until clear and transparent. Then, 5 to 7-week-old C57BL / 6 mice were selected and each mouse was injected with 1 mL of the above starch broth solution by intraperitoneal injection. Two days later, all mice were killed by cervical dislocation; the mice were fixed on a foam board and the abdomen was exposed; 5 ml of pre-cooled sterile PBS was injected into the peritoneum of each mouse, and the abdomen was massaged for three minutes, shaking up and down to remove the peritoneal macrophages; the skin was incised, the ascites was carefully sucked out with a syringe, and then the peritoneum was cut open and the remaining ascites was sucked out with a pipette; after complete collection, centrifugation (1500 rpm, 5 min) was performed, the upper layer of liquid was discarded, 3 mL of red blood cell lysis buffer was added to lyse the red blood cells, centrifuged (1500 rpm, 5 min), the supernatant was discarded, and then centrifuged and washed with sterile PBS to obtain primary peritoneal macrophages.

[0070] The obtained primary macrophages were inoculated into 6-well plates and placed at 37°C with 5% CO 2 After 1 day, all supernatants were aspirated and the prepared 1640 medium (10% fetal bovine serum + 1% penicillin-streptomycin + LPS (1ng / ml) + 1640 medium) was added and cultured in a constant temperature incubator. After 2 days of stimulation, primary macrophages polarized into M1 macrophages.

[0071] After the obtained primary macrophages were successfully polarized into M1 cells, all primary macrophages were collected; primary macrophages were broken by homogenization, and cell debris was removed by differential centrifugation to enrich lysosomes. Their morphology was observed by transmission electron microscopy (TEM), and their particle size and potential were measured by nanoparticle tracking analyzer (NTA).

[0072] 2. Preparation of antiviral lysosomal preparations using chemical modification DSPE-PEG-NTA-Ni was added to the lysosome solution obtained above (the optimal mass ratio of lysosomes to DSPE-PEG-NTA-Ni was 50:1), and the solution was incubated at 37°C for 1 hour. The free DSPE-PEG-NTA-Ni was then separated by ultracentrifugation, and the lysosomes were resuspended. The lysosomes obtained above were evenly mixed with ACE2 protein at a protein mass ratio of 20:1, incubated at 37°C for 1 hour, and the free ACE2 protein was separated by ultracentrifugation, and the antiviral lysosome preparation was finally successfully prepared.

[0073] 3. Preparation of antiviral lysosomal preparations using genetic engineering The macrophages obtained above were added with a lentiviral vector carrying an ACE2 protein plasmid and placed at 37°C with 5% CO 2 After 2 days of stimulation, the primary macrophages were polarized into M1 macrophages and lysosomal preparations were obtained by the above-mentioned lysosomal extraction method.

[0074] 4. Characterization of lysosomes The obtained lysosomes and lysosomal preparations were mixed with ACE2 protein fluorescent antibodies and LAMP-2 protein fluorescent antibodies in turn and observed under a confocal microscope. The results showed that the fluorescent signal of the lysosomal marker LAMP in the lysosomal preparation group and the fluorescent signal of the ACE2 protein group were highly co-localized, indicating that the ACE2 protein was successfully modified. The main protein components of lysosomes and lysosomal preparations were further detected by Western blotting. The results showed that LAMP-2 and ACE2 proteins were positive for both lysosomal preparations prepared by chemical modification and genetic engineering modification ( Figure 1 and Figure 2 ).

[0075] TEM was used to observe the morphology of lysosomes and lysosomal preparations, and the nanoparticle tracking analyzer was used to measure the particle size and potential of lysosomes and lysosomal preparations. The results showed that the surface of lysosomes and lysosomal preparations was smooth and basically spherical, the particle size of lysosomes was approximately 467 nm, the potential was -37.6 mV, the particle size of lysosomal preparations was approximately 492 nm, the potential was -33.8 mV, and there was no significant difference in the physical and chemical properties of lysosomes before and after ACE2 protein modification ( Figure 3 and Figure 4 ).

[0076] The enzyme activities of ACE2 and lysosomes before and after modification were detected by ACE2 enzyme activity detection method, protease enzyme activity detection method and RNA enzyme activity detection method. The results showed that the modification of ACE2 protein would not affect the activity of ACE2 protease, protease and RNA enzyme in lysosomes ( Figure 5 ). Embodiment 2

[0077] This example is an example of the in vitro anti-coronavirus effect of a lysosomal preparation.

[0078] 1. Lysosomal preparations can effectively capture pseudoviruses The quartz electronic microbalance was used to detect the ability of lysosome preparations to capture pseudoviruses. 100 μg of lysosomes and lysosome preparations were taken and suspended on the surface of the chip of the quartz electronic microbalance. The diluted pseudovirus solution then flowed through the chip, and the instrument collected the electronic signals transmitted by the chip. The results showed that compared with simple lysosomes, the lysosome preparation had a greatly improved ability to capture pseudoviruses ( Figure 6 ).

[0079] 2. Lysosomal preparations can effectively internalize pseudoviruses The pseudovirus and lysosome preparation were mixed in a ratio of 5:1 and incubated at 37°C for 1 hour. The solution was then centrifuged by ultracentrifugation to obtain a mixture of pseudovirus and lysosome preparation. The precipitate was then fixed and electron microscopic sections of the mixture were prepared using an electron microscope cryo-ultrathin slicer and observed by TEM. The results showed that there were 4 pseudoviruses inside the lysosome, indicating that the lysosome preparation successfully internalized the pseudovirus ( Figure 7 , respectively prepared by dropping lysosomes on a copper grid; and by slicing lysosomes under an electron microscope and then placing the slices on a copper grid for observation).

[0080] 3. Lysosomal preparations can degrade pseudoviruses The pseudovirus and lysosome preparation were mixed at a ratio of 5:1 and incubated at 37°C. The structural proteins P55 and P24 of the pseudovirus were detected by ELISA; the green fluorescent protein RNA component in the pseudovirus was detected by qPCR; it was found that the viral protein and nucleic acid components were slowly degraded. At 24 hours, the protein signal and nucleic acid signal of the pseudovirus basically disappeared ( Figure 8 and Fig. 9 ).

[0081] 4. Lysosomal preparations inhibit pseudovirus infection of host cells The confocal microplate was inoculated with about 10 4 ACE2-OE 293T cells were cultured in an incubator for 24 h, and then 2×10 4 pfu pseudovirus and 10 μg lysosome preparation were treated for 24 hours, and the intensity of green fluorescent protein expressed during pseudovirus infection was observed by confocal microscopy. At the same time, two control groups, lysosome alone and ACE2 protein alone, and a PBS control group were set up (the number of lysosomes in the lysosome alone group was consistent with that in the lysosome preparation group; the number of ACE2 in the ACE2 protein alone group was consistent with that in the lysosome preparation group). The results showed that compared with other groups, the lysosome preparation group significantly inhibited pseudovirus infection at the cellular level ( Fig.10 ).

[0082] Each well of a 24-well plate was inoculated with approximately 10 4 ACE2-OE 293T cells were cultured in an incubator for 24 h, and then 2×104 pfu of pseudovirus and 10 μg of lysosomal preparation for 24 hours, the cells were collected, and the proportion of cells infected with pseudovirus was analyzed by flow cytometry. At the same time, two control groups, lysosome alone and ACE2 protein alone, and a PBS control group were set up (the number of lysosomes in the lysosome alone group was consistent with that in the lysosome preparation group; the number of ACE2 in the ACE2 protein alone group was consistent with that in the lysosome preparation group). The results showed that compared with other groups, the lysosomal preparation group significantly inhibited pseudovirus infection at the cellular level, reducing the proportion of infected cells from 90% to 1% ( Fig.11 ). Embodiment 3

[0083] This example shows the in vivo distribution of lysosomal preparations in mice and their in vivo anti-coronavirus effects.

[0084] 1. Distribution of lysosomal preparations in mice Lysosomes were labeled with Cy7-NHS, and then the Cy7-labeled lysosomes were prepared into lysosome preparations according to the preparation method of Example 1. Appropriate mice were randomly divided into two groups, one of which was injected with 100 μg / mouse of Cy7-labeled lysosome preparations via tail vein injection, and the other was administered with 100 μg / mouse of Cy7-labeled lysosome preparations via pulmonary spray, and then the fluorescent imaging of the mice was observed in real time using a small animal imager. The results showed that compared with tail vein injection, pulmonary spray administration significantly increased the accumulation of lysosome preparations in the lungs ( Fig.12 The mice were killed by dislocation of the neck, and the heart, liver, spleen, lung and kidney organs were removed by dissection and photographed using a small animal imaging device. The results showed that the vast majority of the lysosomal preparation particles administered by pulmonary spray were accumulated in the lungs ( Fig.13 ).

[0085] 2. Safety of lysosomal preparations C57 mice were given lysosome preparations at 100 μg / mouse via pulmonary spray. Three days later, an appropriate amount of blood was taken from the mouse eye sockets for routine blood tests. Two control groups, lysosome alone and ACE2 protein alone, and a PBS control group were set up. The results showed that after pulmonary spray administration of the lysosome preparation, the number of red blood cells, platelets, and white blood cells did not fluctuate significantly ( Fig.14 ).

[0086] After 3 days, appropriate amount of blood was collected from the eye sockets of each dosed mouse, centrifuged to obtain serum, and then subjected to macro-biochemical analysis. The results showed that after pulmonary spray administration of the lysosomal preparation, all biochemical indices were within the normal range ( Fig.15 ).

[0087] After 3 days, the mice were killed and their internal organs (heart, liver, spleen, lung, and kidney) were removed, fixed, and embedded in paraffin to make 3-4 μm / slice sections, stained with hematoxylin and eosin (HE), and observed under an optical microscope. The results showed that no obvious abnormalities were observed in the internal organs, especially the lungs, after the lysosomal preparation was administered by pulmonary spray ( Fig.16 ).

[0088] 3. Effect of lysosomal preparations on clearing coronavirus in mouse models The mouse model was constructed by expressing human ACE2 protein in mouse lung tissue through transgenic means. Then appropriate hACE2 mice were selected and 2×10 6 pfu of virus; 1 hour later, Cy7-labeled lysosome preparations were administered at 100 μg / mouse by pulmonary spray; 48 hours later, some mice were killed by dislocation of the neck, and the lung tissues of the mice were dissected and removed, embedded and fixed for frozen sections, and stained with DAPI and placed under a microscope to observe the expression of green fluorescent protein in the lungs during viral infection. At the same time, two control groups, lysosome alone and ACE2 protein alone, and a PBS control group were set up (the number of lysosomes in the lysosome alone group was consistent with that in the lysosome preparation group; the number of ACE2 in the ACE2 protein alone group was consistent with that in the lysosome preparation group). The results showed that compared with other groups, the lysosome preparation group significantly inhibited viral infection at the animal level ( Fig.17 ).

[0089] The same steps were followed to conduct an Omicron virus infection study in a mouse model. The results showed that the clearance ability of the lysosomal preparation group was not affected and it could still significantly inhibit the virus from infecting hACE2 mice ( Fig.18 ). Embodiment 4

[0090] This example shows the anti-coronavirus effect of lysosome preparations on human lung organoids 1. Construction of human lung organoids Paracancerous tissue was obtained from the edge of lung cancer tissue removed from lung cancer patients after surgery, and then enzymatically digested into single cells; after 1 week of culture, all cells were collected and resuspended in a mixed solution of lung organ culture medium and Matrigel (ratio 9:1), and 300 μl per well were inoculated on a 24-well plate. After solidification, 300 μl of lung organoid culture medium was added to each well; the medium was changed every 3 days; after 2 weeks, the lung organoids could be passaged when they grew to about 200 μm.

[0091] 2. Lysosomal preparations against coronavirus in human lung organoids The cultured lung organoids were digested into cell suspensions and inoculated into 96-well plates at 500 cells per well. After one week of culture, 200 TCID50 viruses and 10 μg of lysosomal preparations were added. After 24 hours, some lung organoids were taken, RNA was extracted, and the number of viral RNA copies was analyzed. At the same time, two control groups, EIDD-2801 and RBD antibody, and a PBS control group were set up (the number of EIDD-2801 and RBD antibodies was consistent with the number of ACE2 proteins on the surface of the lysosomal preparation). The results showed that compared with conventional viral drugs, the number of viral copies in the lysosomal preparation group was lower ( Fig.19 ).

[0092] After 24 hours, some organoids were taken and immunofluorescence staining of coronavirus S protein was performed and observed under a confocal microscope. The results showed that compared with conventional coronavirus drugs, the lysosomal preparation group significantly inhibited the expression of viral S protein in organoids, and there was basically no S protein signal in the lysosomal preparation group ( Fig. 20 ).

[0093] Then, the same steps as above were followed to conduct an Omicron virus infection study on a human lung organoid model. The results showed that compared with conventional coronavirus drugs, the viral copy number in the lysosomal preparation group was also lower; the S protein was almost not expressed in the lung organoids in the lysosomal preparation group ( Fig.21 and 22 ).

[0094] At the same time, standard score analysis and cluster analysis were performed on the above data. The results showed that: from the perspective of various indicators, the antiviral ability of the lysosomal preparation group was better than that of EIDD-2801 and RBD antibodies; and there were certain differences in the efficacy of EIDD-2801 and RBD antibodies against wild-type and Omicron-type viruses, while there were no differences in the lysosomal preparation group, indicating that the rapid mutation of the virus will basically not affect the efficacy of the constructed lysosomal preparation ( Fig.23 ). Embodiment 5

[0095] This example shows the efficacy of lysosomal preparations against influenza virus in mice 1. Preparation of anti-influenza virus lysosomal preparations using chemical modification Primary macrophages were obtained from the peritoneal cavity of mice according to the steps of Example 1, polarized into M1 primary macrophages by in vitro culture, and lysosomes were extracted. The obtained lysosomes were uniformly mixed with sialylcytidine monophosphate at a mass ratio of 200:1, and an appropriate amount of sialyltransferase was added, and incubated at 37 degrees Celsius for 1 hour.

[0096] 2. Preparation of anti-influenza virus lysosomal preparations using genetic engineering The macrophages were added with a lentiviral vector carrying a sialyltransferase-expressing plasmid and placed at 37°C with 5% CO 2 Incubator with 4% paraformaldehyde and 1% paraformaldehyde for 24 h. The supernatant was aspirated after 2 days, and the prepared 1640 medium (10% fetal bovine serum + 1% penicillin-streptomycin + LPS (1 ng / ml) + 1640 medium) was added and cultured in a constant temperature incubator. After 2 days of stimulation, the primary macrophages polarized into M1 macrophages and lysosomal preparations were obtained by the above-mentioned lysosomal extraction method. The above-obtained lysosomes and anti-influenza virus lysosomal preparations were mixed with elderberry-FITC and LAMP-2 protein fluorescent antibodies in turn and observed under a confocal microscope. The results showed that regardless of whether the lysosomal preparations were prepared by chemical modification or genetic engineering modification, the fluorescent signal of the lysosomal marker LAMP2 was highly co-localized with the fluorescent signal of sialic acid, indicating that the sialic acid modification was successful ( Fig.24 and Fig.25 ).

[0097] 3. Anti-influenza virus efficacy of anti-influenza virus lysosomal preparations in mice C57 mice were anesthetized with 0.5% (volume percentage) pentobarbital (0.1 ml / 10 gbw) intraperitoneally and inoculated with 1000 TCID50 influenza virus by nasal drops; at 2h and 2 days, the anti-influenza virus lysosomal preparation was administered by pulmonary spray at a dose of 100 μg / mouse; after inoculation, the weight of the mice was observed and recorded every day. A PBS group and a non-infected control group were also set up. The results showed that compared with the rapid weight loss of mice in the PBS group, the weight of mice in the anti-influenza virus lysosomal preparation experimental group did not decrease, and there was basically no difference from the non-infected control group ( Fig.26 ).

[0098] After 5 days, all mice were killed by dislocation of the neck, and the lung tissues of the mice were dissected and removed. The water in the lung tissues of the mice was absorbed with filter paper and weighed. The results showed that compared with the lung index of the PBS group, the lung index of the anti-influenza virus lysosomal preparation experimental group was lower and basically consistent with the non-infected control group ( Fig. 27 ). RNA was extracted from the lung tissues, and the influenza virus nucleic acid copy number was detected by q-PCR. The results showed that the influenza virus nucleic acid copy number in the anti-influenza virus lysosomal preparation experimental group was much lower than that in the PBS group ( Fig.28 ).

[0099] Although the present invention has been described with reference to exemplary embodiments, it should be understood that the present invention is not limited to the disclosed exemplary embodiments. Various adjustments or changes may be made to the exemplary embodiments of the present specification without departing from the scope or spirit of the present invention. The scope of the claims should be based on the broadest interpretation to cover all modifications and equivalent structures and functions.

Claims

1. A lysosome-based antiviral agent, It is characterized in that The invention comprises a lysosome and a virus binding molecule located on the surface of the lysosome or a precursor for producing the virus binding molecule.

2. The lysosomal-based antiviral preparation according to claim 1, It is characterized in that The lysosomes are derived from cells that are capable of producing lysosomes.

3. The lysosomal-based antiviral preparation according to claim 2, It is characterized in that The cell is a macrophage, which includes at least one of a primary macrophage, an M1 macrophage and an engineered macrophage.

4. The lysosomal-based antiviral formulation according to claim 1, It is characterized in that The virus binding molecules include receptors for viral surface proteins.

5. The lysosomal-based antiviral preparation according to claim 4, It is characterized in that The receptor is bound to the lysosome via a linker molecule.

6. The lysosomal-based antiviral preparation according to claim 5, It is characterized in that The linker molecule comprises a hydrophobic end, a spacer arm and a binding domain, and the binding domain can bind to the receptor.

7. The lysosomal-based antiviral preparation according to claim 6, It is characterized in that The receptor is a modified receptor.

8. The lysosomal-based antiviral formulation according to claim 1, It is characterized in that The precursor includes sialyl cytidine monophosphate and optionally a sialyltransferase.

9. A method for preparing a lysosomal-based antiviral preparation according to any one of claims 1 to 8.

10. Use of lysosomes in the preparation of drugs for preventing and controlling viral infections, It is characterized in that The lysosomes are engineered to have virus-binding molecules on their surface.

11. Use of a combination of a lysosome and a precursor for producing a virus-binding molecule on the surface of a lysosome in the preparation of a drug for preventing and controlling viral infection.

12. The use according to claims 10 and 11, It is characterized in that The prevention and control includes: Reducing, reducing the amount of virus in a subject, or eliminating the virus in a subject; or Reduce or attenuate viral activity in a subject.

Citation Information

Patent Citations

  • Endolysosomal targeting conjugates for improved delivery of cargo molecules to the endolysosomal compartment of target cells

    CN110944672A

  • COVID-19 prevention and treatment medicine for inhibiting virus receptor ACE2 and application thereof

    CN112057488A

  • E-selectin modified liposome targeted drug delivery system as well as preparation method and application thereof

    CN114344478A

  • Method for blocking asfv infection by interfering with cell receptors

    CN114761039A

  • Application of cell microparticles in treatment of respiratory viral pneumonia

    CN115337404A